



21st Annual International Lung Cancer CONGRESS®

This activity
has been
approved for
20.5 AMA PRA
Category 1
Credits™.

EXCLUSIVE FREE INVITATION FOR FRIENDS OF MOASC

Complimentary registration!* Use code **ILC20MOASC** at gotoper.com/go/ILC20MOASC

Overview:

The 21st Annual **International Lung Cancer Congress®** will provide current, practical information on the management of lung cancer, as well as a look at the novel agents and strategies with the potential to shape the future of lung cancer therapy. Leading international and national experts will provide perspectives on how to apply the latest data on targeted agents, immunotherapy, surgery, and radiation oncology in the clinic. Cutting-edge lectures, panel discussions, multidisciplinary tumor boards, and interactive question-and-answer sessions will provide a unique opportunity for participants to engage with the faculty as they share their perspectives and personal experiences on the clinical challenges and ongoing controversies in lung cancer management.

Benefits of Attending This Year's Meeting:

- Apply the latest breakthrough treatment paradigms in your management of lung cancer
- Evaluate the novel agents and strategies shaping the future of lung cancer therapy
- Incorporate expert perspectives on applying targeted agent, immunotherapy, surgery, and radiation data
- Network with world renowned experts and peers

Hot Topics:

- Changing paradigms for molecular testing in lung cancer at diagnosis and after progression
- How immunotherapy is being incorporated into curative regimens for stage I-III lung cancer
- What should I add to PD-(L)1 blockade in newly diagnosed, stage IV NSCLC?

July 23-25, 2020

**Hyatt Regency Huntington Beach
Huntington Beach, CA**

Program Co-Chairs:



David R. Gandara, MD

Professor of Medicine Emeritus
Division of Hematology/Oncology
Director of Thoracic Oncology
Senior Advisor to the Director
UC Davis Comprehensive Cancer
Center
Sacramento, CA



Roy S. Herbst, MD, PhD

Ensign Professor of Medicine
(Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for
Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT

**Register by June 15, 2020
for this complimentary offer!**

gotoper.com/go/ILC20MOASC

*Discount available for healthcare professionals. Offer expires June 15, 2020. Other restrictions may apply

Accreditation/Credit Designation



Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC, designates this live activity for a maximum of 20.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 20.5 Contact Hours.

Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 20.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

This program is endorsed by



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER
Conquering Thoracic Cancers Worldwide

